Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,deferredLongTermLiab,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,inventory,accountsPayable,otherCurrentAssets,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,changeToNetincome,capitalExpenditures,issuanceOfStock,WC,language,region,quoteType,triggerable,quoteSourceName,currency,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,trailingPE,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,exchange,exchangeDataDelayedBy,marketState,twoHundredDayAverageChangePercent,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,market,priceHint,regularMarketChangePercent,regularMarketDayRange,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Apr 29, 2009) 4","Short Ratio (Apr 29, 2009) 4","Short % of Float (Apr 29, 2009) 4","Short % of Shares Outstanding (Apr 29, 2009) 4","Shares Short (prior month Mar 30, 2009) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry
t0,ELTP,15686245.0,1009180032,1775255,,-482623,,-482623,831283,1865941,-1067503,-1067503,,-20741,,,,0,4395531,5463034,2529590,584880,,-482623,-482623,465684.0,164407480.0,10037563.0,16151929.0,6168351.0,13333.0,26189492.0,1009279.0,-148957989.0,2445432.0,-306841.0,6665102.0,3192768.0,5812531.0,410818.0,6864039.0,12194667.0,3496376.0,1740734.0,5012902.0,929690.0,,-361332.0,-184902.0,-1285739.0,-1285739.0,478205.0,-2220009.0,-749368.0,379288.0,-210895.0,-200169.0,-355387.0,-184902.0,,6382136.0,en-US,US,EQUITY,False,Delayed Quote,USD,0.04734,0.0,0.0,0,0,finmb_528102,Other OTC,"Elite Pharmaceuticals, Inc.",USD,897329,636516,0.0030000024,0.07500006,0.04 - 0.09,-0.047000002,-0.5222222,0.04,0.09,1581386400,1596844800,1597190400,8.6,0.005,0.016,0.048333332,-0.0053333305,-0.110344775,0.055652175,-0.012652174,43394744,2.6875,15,America/New_York,EDT,-14400000,False,False,PNK,0,REGULAR,-0.22734374,ELITE PHARMACEUTICALS INC,0.043,1630507108,-0.0043399967,0.0436,0.0473,0.043,261750,us_market,4,-9.167716,0.043 - 0.0473,0.65,,,0.09,0.04,0.0483,0.0557,897.33k,636.52k,1.01B,,829.65M,22.77%,0.03%,757.07k,0.87,,2.16%,1.34M,,,,,,0.00%,,,,,"Mar 30, 2021","Mar 30, 2021",20.05%,8.29%,5.14%,37.96%,25.38M,0.03,-11.10%,11.87M,3.4M,5.09M,0.0050,,3.19M,0,2.38M,14.73,2.10,0.02,3.19M,1.47M,Value,07647,Healthcare,43,"Elite Pharmaceuticals, Inc. engages in the research, development, manufacture, and licensing of proprietary orally administered controlled-release drug delivery systems and products. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets for the treatment of bariatrics under Adipex-P brand; Hydromorphone HCl 8mg tablets for pains under the Dilaudid brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Oxycodone HCl immediate release 5mg, 10mg, 15mg, 20mg, and 30mg tablets for pains under Roxycodone brand; Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Methadone HCl tablets for pains under the Dolophine brand; and Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets for central nervous system diseases under the Adderall brand, as well as Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; and SequestOX, an immediate release Oxycodone with Naltrexone. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, and infection. Further, the company is developing a range of abuse deterrent opioid products. It has a manufacturing and license agreement with Epic Pharma LLC; development and license agreement with SunGen Pharma, LLC; and strategic marketing alliance with Glenmark Pharmaceuticals, Inc. USA, as well as Lannett Company. Inc. The company was founded in 1984 and is headquartered in Northvale, New Jersey.",Northvale,201 750 2646,NJ,1640908800,United States,http://www.elitepharma.com,86400,165 Ludlow Avenue,201 750 2755,Drug Manufacturers—Specialty & Generic
t-1,ELTP,16164948.0,1009180032,1245669,,2012133,,2012133,826019,3403407,1001169,1001169,,-79673,,,,0,6046582,5045413,2643175,1010964,,2012133,2012133,465684.0,164403560.0,12034605.0,16630632.0,6168351.0,13333.0,28665237.0,1009279.0,-148475366.0,2046962.0,-306841.0,6665094.0,5412785.0,7242350.0,1701932.0,6996289.0,14538170.0,3296207.0,2745293.0,4802007.0,700905.0,229451.0,-8695.0,-37706.0,-150452.0,-150452.0,-716353.0,1047129.0,1235287.0,376426.0,-339444.0,779765.0,-872089.0,-50231.0,,7295820.0,en-US,US,EQUITY,False,Delayed Quote,USD,0.04734,0.0,0.0,0,0,finmb_528102,Other OTC,"Elite Pharmaceuticals, Inc.",USD,897329,636516,0.0030000024,0.07500006,0.04 - 0.09,-0.047000002,-0.5222222,0.04,0.09,1581386400,1596844800,1597190400,8.6,0.005,0.016,0.048333332,-0.0053333305,-0.110344775,0.055652175,-0.012652174,43394744,2.6875,15,America/New_York,EDT,-14400000,False,False,PNK,0,REGULAR,-0.22734374,ELITE PHARMACEUTICALS INC,0.043,1630507108,-0.0043399967,0.0436,0.0473,0.043,261750,us_market,4,-9.167716,0.043 - 0.0473,0.65,,,0.09,0.04,0.0483,0.0557,897.33k,636.52k,1.01B,,829.65M,22.77%,0.03%,757.07k,0.87,,2.16%,1.34M,,,,,,0.00%,,,,,"Mar 30, 2021","Mar 30, 2021",20.05%,8.29%,5.14%,37.96%,25.38M,0.03,-11.10%,11.87M,3.4M,5.09M,0.0050,,3.19M,0,2.38M,14.73,2.10,0.02,3.19M,1.47M,Value,07647,Healthcare,43,"Elite Pharmaceuticals, Inc. engages in the research, development, manufacture, and licensing of proprietary orally administered controlled-release drug delivery systems and products. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets for the treatment of bariatrics under Adipex-P brand; Hydromorphone HCl 8mg tablets for pains under the Dilaudid brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Oxycodone HCl immediate release 5mg, 10mg, 15mg, 20mg, and 30mg tablets for pains under Roxycodone brand; Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Methadone HCl tablets for pains under the Dolophine brand; and Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets for central nervous system diseases under the Adderall brand, as well as Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; and SequestOX, an immediate release Oxycodone with Naltrexone. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, and infection. Further, the company is developing a range of abuse deterrent opioid products. It has a manufacturing and license agreement with Epic Pharma LLC; development and license agreement with SunGen Pharma, LLC; and strategic marketing alliance with Glenmark Pharmaceuticals, Inc. USA, as well as Lannett Company. Inc. The company was founded in 1984 and is headquartered in Northvale, New Jersey.",Northvale,201 750 2646,NJ,1640908800,United States,http://www.elitepharma.com,86400,165 Ludlow Avenue,201 750 2755,Drug Manufacturers—Specialty & Generic
t-2,ELTP,14151164.0,1009180032,1147739,,2484062,,2481562,796966,3621396,1340257,1340257,,-79753,,,,2500,7399892,6059635,3778496,1143805,,2481562,2481562,465684.0,164401909.0,12989070.0,14616848.0,6168351.0,13333.0,27605918.0,1009279.0,-150487499.0,3129979.0,-306841.0,6709312.0,4365667.0,7010803.0,1682333.0,7155831.0,13275091.0,4075972.0,2791750.0,4462563.0,589428.0,,-1462220.0,-77449.0,-287265.0,-245042.0,95261.0,1578028.0,1900519.0,381094.0,1103840.0,294199.0,-996762.0,-80848.0,42223.0,6264288.0,en-US,US,EQUITY,False,Delayed Quote,USD,0.04734,0.0,0.0,0,0,finmb_528102,Other OTC,"Elite Pharmaceuticals, Inc.",USD,897329,636516,0.0030000024,0.07500006,0.04 - 0.09,-0.047000002,-0.5222222,0.04,0.09,1581386400,1596844800,1597190400,8.6,0.005,0.016,0.048333332,-0.0053333305,-0.110344775,0.055652175,-0.012652174,43394744,2.6875,15,America/New_York,EDT,-14400000,False,False,PNK,0,REGULAR,-0.22734374,ELITE PHARMACEUTICALS INC,0.043,1630507108,-0.0043399967,0.0436,0.0473,0.043,261750,us_market,4,-9.167716,0.043 - 0.0473,0.65,,,0.09,0.04,0.0483,0.0557,897.33k,636.52k,1.01B,,829.65M,22.77%,0.03%,757.07k,0.87,,2.16%,1.34M,,,,,,0.00%,,,,,"Mar 30, 2021","Mar 30, 2021",20.05%,8.29%,5.14%,37.96%,25.38M,0.03,-11.10%,11.87M,3.4M,5.09M,0.0050,,3.19M,0,2.38M,14.73,2.10,0.02,3.19M,1.47M,Value,07647,Healthcare,43,"Elite Pharmaceuticals, Inc. engages in the research, development, manufacture, and licensing of proprietary orally administered controlled-release drug delivery systems and products. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets for the treatment of bariatrics under Adipex-P brand; Hydromorphone HCl 8mg tablets for pains under the Dilaudid brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Oxycodone HCl immediate release 5mg, 10mg, 15mg, 20mg, and 30mg tablets for pains under Roxycodone brand; Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Methadone HCl tablets for pains under the Dolophine brand; and Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets for central nervous system diseases under the Adderall brand, as well as Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; and SequestOX, an immediate release Oxycodone with Naltrexone. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, and infection. Further, the company is developing a range of abuse deterrent opioid products. It has a manufacturing and license agreement with Epic Pharma LLC; development and license agreement with SunGen Pharma, LLC; and strategic marketing alliance with Glenmark Pharmaceuticals, Inc. USA, as well as Lannett Company. Inc. The company was founded in 1984 and is headquartered in Northvale, New Jersey.",Northvale,201 750 2646,NJ,1640908800,United States,http://www.elitepharma.com,86400,165 Ludlow Avenue,201 750 2755,Drug Manufacturers—Specialty & Generic
t-3,ELTP,-2580953.0,1009180032,943879,,1077349,,1077349,868777,2976394,830600,830600,,-79431,,,,0,7538744,6708144,4562350,246749,,1077349,1077349,465684.0,150319552.0,16033042.0,-2115269.0,6168351.0,13333.0,27821733.0,841081.0,-152969061.0,4349505.0,-306841.0,6648878.0,2787640.0,8635261.0,1770686.0,7456077.0,13251094.0,4370171.0,2936039.0,5566403.0,2074144.0,,-116615.0,37276.0,811404.0,811404.0,293823.0,1656103.0,807423.0,373604.0,-1423931.0,-263325.0,862973.0,-14000.0,42223.0,4615833.0,en-US,US,EQUITY,False,Delayed Quote,USD,0.04734,0.0,0.0,0,0,finmb_528102,Other OTC,"Elite Pharmaceuticals, Inc.",USD,897329,636516,0.0030000024,0.07500006,0.04 - 0.09,-0.047000002,-0.5222222,0.04,0.09,1581386400,1596844800,1597190400,8.6,0.005,0.016,0.048333332,-0.0053333305,-0.110344775,0.055652175,-0.012652174,43394744,2.6875,15,America/New_York,EDT,-14400000,False,False,PNK,0,REGULAR,-0.22734374,ELITE PHARMACEUTICALS INC,0.043,1630507108,-0.0043399967,0.0436,0.0473,0.043,261750,us_market,4,-9.167716,0.043 - 0.0473,0.65,,,0.09,0.04,0.0483,0.0557,897.33k,636.52k,1.01B,,829.65M,22.77%,0.03%,757.07k,0.87,,2.16%,1.34M,,,,,,0.00%,,,,,"Mar 30, 2021","Mar 30, 2021",20.05%,8.29%,5.14%,37.96%,25.38M,0.03,-11.10%,11.87M,3.4M,5.09M,0.0050,,3.19M,0,2.38M,14.73,2.10,0.02,3.19M,1.47M,Value,07647,Healthcare,43,"Elite Pharmaceuticals, Inc. engages in the research, development, manufacture, and licensing of proprietary orally administered controlled-release drug delivery systems and products. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets for the treatment of bariatrics under Adipex-P brand; Hydromorphone HCl 8mg tablets for pains under the Dilaudid brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Oxycodone HCl immediate release 5mg, 10mg, 15mg, 20mg, and 30mg tablets for pains under Roxycodone brand; Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Methadone HCl tablets for pains under the Dolophine brand; and Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets for central nervous system diseases under the Adderall brand, as well as Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; and SequestOX, an immediate release Oxycodone with Naltrexone. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, and infection. Further, the company is developing a range of abuse deterrent opioid products. It has a manufacturing and license agreement with Epic Pharma LLC; development and license agreement with SunGen Pharma, LLC; and strategic marketing alliance with Glenmark Pharmaceuticals, Inc. USA, as well as Lannett Company. Inc. The company was founded in 1984 and is headquartered in Northvale, New Jersey.",Northvale,201 750 2646,NJ,1640908800,United States,http://www.elitepharma.com,86400,165 Ludlow Avenue,201 750 2755,Drug Manufacturers—Specialty & Generic
